Articles related to OVARIAN CANCER
Managing Microcyst-Like Epithelial Keratopathy Related to Cancer Therapy
As we embrace the era of antibody-drug conjugates (ADCs) in cancer therapy, it’s crucial to understand their impact on ocular health. With ADCs like mirvetuximab offering new hope for ovarian cancer patients, effective partnerships between optometrists and oncologists are key to managing associated ocular adverse events.
Optometry October 30th 2023
Mirvetuximab Soravtansine Improved Overall Survival for Patients with Folate Receptor Alpha-High Platinum-Resistant Ovarian Cancer
The MIRASOL trial has unveiled mirvetuximab soravtansine’s potential to revolutionize the treatment landscape for patients with platinum-resistant ovarian cancer. Physicians are invited to delve into the data that positions this novel therapy as a potential new standard of care.
Oncology, Medical August 7th 2023
New Approach to Adoptive T-Cell Therapy Shows Promise for Boosting Immune Response in Ovarian Cancer
Researchers at Roswell Park Comprehensive Cancer Center have unveiled a novel approach using bispecific T-cell engagers (BiTEs) to enhance immune responses against ovarian cancer. This promising pathway may lead to improved therapeutic options for patients unresponsive to conventional immunotherapies.
Obstetrics & Gynecology August 1st 2023
Pfizer Pushes Forward In Drug-Resistant Breast Cancer
Pfizer is lagging behind its peers with Ibrance, but the pharma giant is attempting to unveil the potential of CDK2 inhibitors to overcome CDK4/6 resistance. At the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer and Blueprint gave presentations on posters about their respective agents, and Incyte, Cyclacel, and a few private biotechs also had clinical trials going on. Although there are some positive signs, the research is still in its very early stages, and it is not apparent whether CDK2 inhibition is a workable monotherapy method.
Hematology June 5th 2023
Long-term Health Consequences After Ovarian Removal at Benign Hysterectomy
The study followed nearly 143,000 women who underwent hysterectomy for a benign condition over a 20-year-period and compared outcomes between those who had bilateral salpingo-oophorectomy (BSO) and those who didn’t. Younger (under age 45) women who had BSO had a higher 10-year cumulative risk of hospitalization for CVD. Women aged 45 to 54 with BSO had a higher 10-year risk for developing cancer. Based on the findings, the authors suggest a cautious approach to ovarian removal in postmenopausal women and recommend preserving ovaries in premenopausal women without a high risk for ovarian cancer.
Family Medicine/General Practice May 3rd 2023